Caristo Expected to Break New Ground in Cardiac Risk Assessment at SCCT 2025

New Horizons in Cardiac Risk Assessment: Caristo at SCCT 2025



Caristo Diagnostics is set to revolutionize cardiovascular diagnostics with its latest findings, slated for presentation at the 2025 annual scientific meeting of the Society of Cardiovascular Computed Tomography (SCCT) in Montreal. From July 17 to 20, medical professionals will gather to discuss transformative technologies in cardiac care. Caristo's focus on its innovative CaRi-Heart® technology, designed to measure coronary inflammation and predict cardiac risk, underscores a major shift in traditional cardiovascular assessments.

Innovations in Predicting Cardiac Risk



The centerpiece of Caristo's presentation will feature groundbreaking data from Dr. Kenneth Chan, a clinical research fellow in cardiology at the University of Oxford. His abstract, titled "Coronary Inflammation Predicts Cardiac Risk in Patients with No and Moderate Coronary Calcification," details findings from a significant study of 20,000 patients. This research highlights the efficacy of CaRi-Heart's FAI-Score biomarker, particularly among patients long considered low-risk due to low or nonexistent calcium scores. This revelation has the potential to reshape risk stratification for many patients, lending greater accuracy to what has typically been viewed as stable outcomes.

Dr. Chan is scheduled to present his findings on July 18 at 9:30 AM in the SCCT Exhibit Hall. His work emphasizes that evaluating coronary inflammation may uncover hidden risks previously overlooked in standard imaging techniques.

Large-Scale Implementation in NHS Hospitals



The potential of CaRi-Heart technology is further underscored by data resulting from its implementation across five National Health Service (NHS) hospitals in the UK. These insights will be fully discussed during the Caristo symposium on July 19 at 7 AM, featuring prominent cardiologists, including Dr. Tim Fairbairn from Liverpool Heart Chest Hospital and Ron Blankstein, MD, from Harvard Medical School. Their shared expertise will shed light on the technology's effectiveness in tailoring patient management and managing cardiovascular risk based on inflammation-driven metrics.

Regulatory Milestones and Future Prospects



Caristo diagnostics is not merely sitting on its laurels. The company achieved two critical U.S. regulatory milestones in 2025. In February, the Food and Drug Administration (FDA) granted clearance for the CaRi-Plaque™ technology, allowing for plaque and stenosis quantification. Following this, in March, the American Medical Association (AMA) CPT Panel approved a new Category III CPT® code for CaRi-Heart technology. These achievements highlight the industry's recognition of Caristo's innovative approach to cardiovascular risk assessment, paving the way for enhanced clinical adoption and integration.

CEO Frank Cheng expresses enthusiasm about the upcoming SCCT presentations, stating, "We are excited to present our latest clinical and research results, demonstrating the significant impact we are making on health outcomes for patients."

Sessions to Watch Out for at SCCT



Beyond Caristo's dedicated presentations, the SCCT conference offers a rich program filled with discussions on contemporary techniques in cardiac imaging and artificial intelligence applications in medicine.

For instance, attendees will have the opportunity to participate in an interactive workshop focused on artificial intelligence and machine learning applications in cardiovascular studies on July 17. The debate on the usefulness of pericoronary fat analysis on July 18 further exemplifies the diverse range of topics being explored at the conference.

Conclusion



As Caristo Diagnostics prepares to unveil these critical advancements in cardiac imaging and risk management at SCCT 2025, the company's commitment to innovation in cardiovascular health continues to promise significant improvements in patient outcomes. This year's conference not only signifies a platform for sharing pioneering research but also highlights the ongoing evolution of cardiac care.

For those interested, Caristo will be offering demonstrations of their technologies at Booth #304, providing attendees with direct insights into the future of heart disease prevention and assessment.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.